Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Authors
Raymond, EDahan, L
Raoul, J
Bang, Y
Borbath, I
Lombard-Bohas, C
Valle, Juan W
Metrakos, P
Smith, D
Vinik, A
Chen, J
Hörsch, D
Hammel, P
Wiedenmann, B
Van Cutsem, E
Patyna, S
Lu, Dongr
Blanckmeister, C
Chao, R
Ruszniewski, P
Affiliation
Service Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France.Issue Date
2011-02-10
Metadata
Show full item recordAbstract
The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.Citation
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364 (6):501-13 N. Engl. J. Med.Journal
New England Journal of MedicineDOI
10.1056/NEJMoa1003825PubMed ID
21306237Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1003825
Scopus Count
Related articles
- Everolimus for advanced pancreatic neuroendocrine tumors.
- Authors: Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
- Issue date: 2011 Feb 10
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
- Authors: Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators
- Issue date: 2014 Jul 17
- Activity of sunitinib in patients with advanced neuroendocrine tumors.
- Authors: Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS
- Issue date: 2008 Jul 10
- Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
- Authors: Deeks ED, Raymond E
- Issue date: 2011 Oct 1
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
- Authors: Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M
- Issue date: 2014 Mar 1